Aurobindo Pharma Sees Robust Call Option Activity Ahead of March Expiry

Strong Call Option Interest at Key Strike Price

The most active call options for Aurobindo Pharma are concentrated at the ₹1,270 strike price, with 2,904 contracts traded recently. This surge in activity generated a turnover of ₹630.10 lakhs, reflecting substantial market interest in the stock’s near-term upside potential. Open interest stands at 853 contracts, indicating that traders are maintaining their positions rather than merely engaging in speculative intraday trades.

The underlying stock price closed at ₹1,261.5, just 1.08% shy of its 52-week high of ₹1,278.6, underscoring the proximity to a critical resistance level. This near-record price level, combined with the heavy call option volume, suggests that market participants are positioning for a possible breakout or sustained rally in the coming weeks.

Technical Indicators and Price Performance

Aurobindo Pharma has outperformed its sector by 0.27% on the day, with a 1.03% gain compared to the Pharmaceuticals & Biotechnology sector’s 1.25% rise and the Sensex’s more modest 0.29% advance. The stock has recorded four consecutive days of gains, delivering a cumulative return of 5.82% during this period. This consistent upward trajectory is supported by the stock trading above all major moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling a strong bullish trend.

Investor participation has notably increased, with delivery volumes on 9 March reaching 12.38 lakh shares, a 139.5% rise compared to the five-day average. This surge in delivery volume indicates genuine accumulation rather than short-term speculative trading, reinforcing the positive technical outlook.

Mojo Score and Market Capitalisation Context

Aurobindo Pharma currently holds a Mojo Score of 68.0, with a Mojo Grade of Hold, reflecting a cautious stance after a recent downgrade from Buy on 1 December 2025. Despite this, the stock’s market capitalisation remains robust at ₹72,327 crore, categorising it as a mid-cap entity within the Pharmaceuticals & Biotechnology sector. The market cap grade of 2 indicates moderate size and liquidity, which is corroborated by the stock’s ability to handle trade sizes of approximately ₹2.86 crore based on 2% of its five-day average traded value.

The downgrade in rating suggests that while the stock exhibits strong technicals and investor interest, some caution remains regarding valuation or sector-specific headwinds. Nonetheless, the current bullish positioning in the options market may reflect traders’ anticipation of positive developments or earnings surprises ahead.

Expiry Patterns and Trader Sentiment

The expiry date of 30 March 2026 is a focal point for options traders, with the concentration of call options at ₹1,270 strike price signalling a consensus expectation that the stock will test or surpass this level by month-end. The open interest data supports this view, as traders are not only initiating but also holding onto bullish positions, suggesting confidence in the stock’s near-term upside.

Such positioning often precedes significant price moves, as traders hedge or speculate on anticipated catalysts such as quarterly results, regulatory approvals, or sectoral developments. Given Aurobindo Pharma’s recent outperformance and technical strength, the options market activity aligns with a constructive outlook.

Liquidity and Trading Dynamics

The stock’s liquidity profile is favourable, with delivery volumes surging and the ability to absorb sizeable trades without excessive price impact. This liquidity is crucial for options traders who require efficient execution and minimal slippage. The combination of rising volumes, strong open interest, and proximity to a 52-week high creates an environment conducive to active trading and potential volatility.

Outlook and Investor Considerations

Investors and traders should weigh the current bullish signals against the recent Mojo Grade downgrade and sector dynamics. While the technical indicators and options market activity point to a positive near-term trajectory, the Hold rating suggests that valuation or external factors may temper upside potential.

Given the stock’s proximity to its 52-week high and the strong call option interest at ₹1,270 strike price, a breakout above this level could trigger further gains. Conversely, failure to sustain momentum may lead to consolidation or profit-taking. Monitoring open interest changes and delivery volumes in the coming days will provide additional clues on market sentiment.

Overall, Aurobindo Pharma remains a key stock to watch within the Pharmaceuticals & Biotechnology sector, with its derivatives activity offering valuable insights into investor expectations and risk appetite.

Summary of Key Metrics

• Underlying stock price: ₹1,261.5
• 52-week high: ₹1,278.6 (1.08% away)
• Call option strike price: ₹1,270
• Contracts traded: 2,904
• Turnover: ₹630.10 lakhs
• Open interest: 853 contracts
• Consecutive gains: 4 days, 5.82% return
• Delivery volume (9 Mar): 12.38 lakh shares (+139.5%)
• Mojo Score: 68.0 (Hold, downgraded from Buy on 1 Dec 2025)
• Market cap: ₹72,327 crore (Mid Cap)
• Market cap grade: 2
• Liquidity: Supports trade size of ₹2.86 crore

Conclusion

Aurobindo Pharma’s active call option trading and strong technical performance highlight a bullish sentiment among market participants. While the stock’s recent Mojo Grade downgrade advises caution, the sustained investor interest and favourable liquidity conditions suggest that the pharmaceutical company remains well positioned for potential upside in the near term. Traders should continue to monitor expiry dynamics and volume trends to gauge the evolving market outlook.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →